DARK Classics in Chemical Neuroscience: Psilocybin

Geiger and colleagues introduce psilocybin as the principal psychoactive alkaloid found in a range of ‘‘magic mushrooms’’ and place it in the broader chemical family of indolealkylamine compounds related to serotonin, melatonin and N,N-dimethyltryptamine. The text summarises basic physico-chemical contrasts between psilocybin and its active metabolite psilocin (for example, psilocybin: six hydrogen bond acceptors, three hydrogen bond donors, logP 0.03; psilocin: three acceptors, two donors, logP 1.32), and notes that psilocybin acts as a prodrug that is rapidly dephosphorylated to the more lipophilic psilocin, which can cross the blood–brain barrier to produce psychoactive effects. Beyond chemistry, the introduction sketches psilocybin’s historical arc: its isolation and synthesis by Albert Hofmann in the late 1950s, clinical and recreational rise in the 1960s, scheduling and resultant research hiatus after 1970, and recent re-emergence of clinical interest. The authors frame the review to cover synthesis and biosynthesis, metabolism, pharmacology, adverse reactions, legal/manufacturing constraints and the emerging clinical evidence for disorders such as obsessive–compulsive disorder, substance use disorders and depression in both terminal illness and treatment-resistant cases.

The extracted text does not present a discrete Methods section nor a formal description of systematic search methods, inclusion criteria, or meta-analytic techniques. The paper is a narrative, historically informed review that synthesises chemical, pharmacological, toxicological and clinical literature on psilocybin. Material integrated into the review includes chemical synthesis routes (Hofmann’s original synthetic sequence and subsequent modifications), fungal biosynthetic pathways (enzymes designated PsiD, PsiH, PsiK, PsiM and intermediates such as tryptamine, 4-hydroxytryptamine, norbaeocystin and baeocystin), metabolic studies identifying urinary metabolites and hepatic glucuronidation (UGT1A10, UGT1A9), receptor binding and pharmacodynamic evidence, preclinical dosing and toxicology data, observational surveys of recreational use, and results from preliminary clinical trials and proof-of-concept studies addressing addiction and psychiatric indications. Because formal methods for literature identification are not reported in the extracted text, it is not possible to determine comprehensiveness or whether a systematic selection process was used.

Chemistry and biosynthesis: The review outlines both the fungal biosynthetic route and Hofmann’s synthetic chemistry. In fungi, tryptophan is decarboxylated by PsiD to tryptamine, hydroxylated by PsiH to 4-hydroxytryptamine, phosphorylated by PsiK to norbaeocystin, methylated by PsiM to baeocystin and then methylated again to yield psilocybin; psilocybin and psilocin are in enzymatic equilibrium. Hofmann’s laboratory synthesis is described stepwise, beginning from benzyl-protected 4-hydroxyindole and proceeding through functionalisation, reduction, deprotection and phosphorylation, with later chemists reporting yield-improving modifications. Metabolism and pharmacokinetics: After oral ingestion, psilocybin is rapidly dephosphorylated to psilocin during first-pass metabolism by an unidentified enzyme. Psilocin undergoes both Phase I (oxidation to 4-hydroxyindole-3-acetaldehyde and further oxidation or reduction) and predominantly Phase II metabolism (≥80% glucuronidation via UGT1A10 in the small intestine and UGT1A9 in the liver) to yield psilocin O-glucuronide, which is renally excreted. A cited study reports an elimination half-life of psilocin of approximately 3 hours (± 1.1 hours) in healthy adults. Pharmacology and receptor profile: Psilocin shows highest binding at serotonin receptors 5-HT1D, 5-HT2B, 5-HT2C, 5-HT5, 5-HT6 and 5-HT7, with moderate affinity at 5-HT1A, 5-HT1B and 5-HT2A. It also has activity at histamine H1, alpha-2 adrenergic subtypes (α2A, α2B), dopamine D3 and inhibits the sodium-dependent serotonin transporter (SERT). The authors emphasise the prevailing view that partial agonism at 5-HT2A underpins the psychedelic subjective effects, while broader receptor interactions shape the overall psychoactive profile. The review summarises mechanistic observations such as 5-HT1A presynaptic autoreceptor effects in the dorsal and median raphe nuclei, differential receptor downregulation patterns and rapid tachyphylaxis to 5-HT2A stimulation; tolerance is reported to begin after a single dose, return to 50% of baseline in 3–7 days and baseline within 1–4 weeks depending on exposure. Dosing, safety and toxicology: Typical human subjective effects last approximately 4–7 hours, with after-effects from 1 to 24 hours. Animal behavioural dosing has used 0.25–10 mg/kg; the reported rat LD50 for psilocin is 293 mg/kg. Common acute adverse events in clinical settings include transient tachycardia, anxiety, nausea, vomiting, diarrhoea, emotional lability, delusions, feelings of impending doom and confusion. More serious but rare concerns discussed include hallucinogen persisting perception disorder (HPPD), seizures (risk increased by physiological stressors and drug interactions), and a potential long-term risk of cardiac valvulopathy mediated by 5-HT2B receptor agonism. The review flags tramadol as a notable contraindicated co-medication due to seizure risk, and notes interactions with monoamine oxidase inhibitors and psychostimulants, variable effects when combined with cannabis, and attenuation of effects by ethanol, GHB, SSRIs and benzodiazepines. Legal/manufacturing context: Psilocybin is Schedule I in the United States, restricting production and research; most developed countries likewise prohibit possession and use, with exceptions such as legal ‘‘truffles’’ in the Netherlands. Cultivation and wild foraging pose identification risks that can lead to severe poisoning from misidentified species. Clinical and observational evidence: The authors review early clinical and pilot studies suggesting therapeutic potential across several indications, while emphasising limitations in study design and scale. For cancer-related anxiety and depression, randomised and controlled trials are reported to show rapid, notable and lasting reductions in anxiety and depression; a six-and-a-half-month follow-up of Ross et al. reported response rates in the 60–80% range on different validated measures, and a Griffiths et al. study reported about 80% continued decreases in depression and anxiety at six months. In tobacco cessation, a small open-label study linked intensity of mystical-type experiences to better outcomes: 80% showed biologically verified seven-day point-prevalence abstinence at six months, 67% were abstinent at 12 months, and a 2.5-year follow-up reported 75% abstinence; the review notes the absence of a control group in that study. Alcohol use studies are described as proof-of-concept and preliminary; one study reported significant increases in abstinence maintained to 36 weeks, with intensity of the initial session correlating with subsequent reductions in craving and increased abstinence self-efficacy. For treatment-resistant depression and obsessive–compulsive disorder the authors cite promising but preliminary findings, noting some trials reported no serious unexpected adverse effects, with common expected short-term difficulties such as anxiety, nausea and headache. Epidemiology and recreational harms: Large surveys of recreational users indicate that challenging experiences are common: one survey of roughly 2,000 participants found 39% rated a challenging experience among the top five most difficult experiences of their lives, 11% reported risking physical harm, 2.6% reported aggressive or violent behaviour and 2.7% sought medical help during a ‘‘bad trip’’. Hospital admissions related to mushroom ingestion (n=44 in one cited series) were most often for dysphoria and short-term behavioural alterations. The review contrasts higher rates of adverse events in uncontrolled settings with generally lower rates in screened, prepared, clinical settings.

The authors interpret the accumulated evidence as indicating that psilocybin is both a ‘‘dark classic’’ in chemical neuroscience and a compound with renewed therapeutic promise, particularly for cancer-related distress, certain substance use disorders and some mood disorders. They place the recent positive clinical signals in the context of a long history of cultural use, early scientific discovery, a decades-long research interruption following scheduling, and the current cautious revival of clinical work. In discussing strengths, the review highlights the relative safety observed in controlled clinical trials, the plausibility of a mechanistic basis for therapeutic effects via serotonergic modulation and related neuroendocrine changes, and the striking persistence of clinical benefit after single or few administrations in several reports. The authors also stress that therapeutic benefit in trials has been strongly associated with the occurrence and intensity of ‘‘mystical’’ or profound subjective experiences. Key limitations acknowledged include the paucity of large, well-controlled randomised trials for many indications, methodological shortcomings in several addiction studies (absence of randomisation or comparator arms), incomplete characterisation of psilocybin’s complete metabolic pathway and long-term toxicology, and the challenges of conducting double-blind trials with an intervention that produces conspicuous subjective effects. Regulatory and practical barriers are also emphasised: Schedule I controls, licensing requirements, difficulties in intellectual property protection for an old compound, production constraints, and the need to replicate clinical-trial safeguards (screening, preparation, monitoring and follow-up) if psilocybin were to be used clinically. Finally, the authors recommend cautious optimism: further rigorous clinical trials are needed to confirm efficacy and safety, and any future regulatory pathway should incorporate the protective procedures used in research settings to mitigate medical and behavioural risks. They warn that benefits seen in controlled trials may not generalise to unscreened populations or uncontrolled environments.